노인 불면증의 약물치료
Pharmacotherapy for Insomnia of the Elderly
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Insomnia is a common disease in the elderly. It is caused by various etiologies and their combinations. Therefore, treatment should be tailored to the individual. Cognitive-behavioral therapy for insomnia (CBT-I) is the treatment of choice for chronic insomnia; however, hypnotics are commonly used as a primary treatment in the clinical practice. The hypnotics approved for insomnia management in Korea include zolpidem, eszopiclone, triazolam, doxepin, prolonged-release melatonin, and flurazepam. Although not approved, sedative antidepressants and antipsychotics are also frequently used. When prescribing hypnotics to elderly patients, the side effects and limitations of pharmacotherapy should be explained in advance, and the lowest effective dose and “as needed” prescription should be employed. Moreover, the adverse effects should be considered, including dependence, in the elderly. When reducing the medication dose, gradual tapering is safe and realistic considering the withdrawal symptoms. Even in long-term pharmacotherapy, the combination of sleep hygiene education and CBT-I should be considered to increase the effectiveness of and satisfaction from the insomnia treatment, and minimize the medication dose.
Abstract
Insomnia is a common disease in the elderly. It is caused by various etiologies and their combinations. Therefore, treatment should be tailored to the individual. Cognitive-behavioral therapy for insomnia (CBT-I) is the treatment of choice for chronic insomnia; however, hypnotics are commonly used as a primary treatment in the clinical practice. The hypnotics approved for insomnia management in Korea include zolpidem, eszopiclone, triazolam, doxepin, prolonged-release melatonin, and flurazepam. Although not approved, sedative antidepressants and antipsychotics are also frequently used. When prescribing hypnotics to elderly patients, the side effects and limitations of pharmacotherapy should be explained in advance, and the lowest effective dose and “as needed” prescription should be employed. Moreover, the adverse effects should be considered, including dependence, in the elderly. When reducing the medication dose, gradual tapering is safe and realistic considering the withdrawal symptoms. Even in long-term pharmacotherapy, the combination of sleep hygiene education and CBT-I should be considered to increase the effectiveness of and satisfaction from the insomnia treatment, and minimize the medication dose.
참고문헌 (32)
- Kim WH, "Prevalence of insomnia and associated factors in a community sample of elderly individuals in South Korea", Int Psychogeriatr, 25, pp.1729~1737 (2013)
- American Academy of Sleep Medicine, "International classification of sleep disorders" (2014), American Academy of Sleep Medicine
- Perlis ML, "Insomnia as a risk factor for onset of depression in the elderly", Behav Sleep Med, 4, pp.104~113 (2006)
- Ozminkowski RJ, "The direct and indirect costs of untreated insomnia in adults in the United States", Sleep, 30, pp.263~273 (2007)
- Ford DE, "Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention?", JAMA, 262, pp.1479~1484 (1989)
- Kim L, "Sleep physiology and common sleep disorders in the elderly", Sleep Med Psychophysiol, 14, pp.5~12 (2007)
- Oh JE, "Sleep disorders in the elderly", Korean J Clin Geri, 16, pp.37~43 (2015)
- 이은, "불면증의 인지행동치료", 대한의사협회지, 63(8), pp.477~483 (2020), 대한의사협회
- Schutte-Rodin S, "Clinical guideline for the evaluation and management of chronic insomnia in adults", J Clin Sleep Med, 4, pp.487~504 (2008)
- Kang SG, "Textbook of clinical neuropsychopharmacology", pp.449~457 (2019), Sigmapress
- Winkelman JW., "Clinical practice. Insomnia disorder", N Engl J Med, 373, pp.1437~1444 (2015)
- Kolla BP, "Zolpidem is independently associated with increased risk of inpatient falls", J Hosp Med, 8, pp.1~6 (2013)
- Kilduff TS, "Principles and practice of sleep medicine", pp.424~431 (2017), Elsevier
- Sateia MJ, "Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults : an American Academy of Sleep Medicine clinical practice guideline", J Clin Sleep Med, 13, pp.307~349 (2017)
- AlDawsari A, "Use of sedative-hypnotic medications and risk of dementia : a systematic review and meta-analysis", Br J Clin Pharmacol, 88, pp.1567~1589 (2022)
- Chen PL, "Risk of dementia in patients with insomnia and long-term use of hypnotics : a population-based retrospective cohort study", PLoS One, 7, pp.e49113~ (2012)
- Lee J, "Use of sedative-hypnotics and the risk of Alzheimer’s dementia : a retrospective cohort study", PLoS One, 13, pp.e0204413~ (2018)
- Tseng LY, "Benzodiazepines, z-hypnotics, and risk of dementia: special considerations of half-lives and concomitant use", Neurotherapeutics, 17, pp.156~164 (2020)
- Dubovsky SL., "Kaplan and Sadock's comprehensive textbook of psychiatry", pp.2781~2791 (2005), Lippincott Williams & Wilkin
- Morin CM, "Long-term outcome after discontinuation of benzodiazepines for insomnia : a survival analysis of relapse", Behav Res Ther, 43, pp.1~14 (2005)
- Sanchez-Barcelo EJ, "Clinical uses of melatonin in neurological diseases and mental and behavioural disorders", Curr Med Chem, 24, pp.3851~3878 (2017)
- Cardinali DP, "Assessing the efficacy of melatonin to curtail benzodiazepine", Z drug abuse, 2016, pp.109, 12~23
- 김석주, "불면증의 약물치료", 대한의사협회지, 52(7), pp.719~726 (2009), 대한의사협회
- Enomoto M, "Long-term use of hypnotics : analysis of trends and risk factors", Gen Hosp Psychiatry, 62, pp.49~55 (2020)
- Winokur A, "Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients : a pilot study", Biol Psychiatry, 48, pp.75~78 (2000)
- Krystal AD, "Efficacy and safety of esmirtazapine in elderly patients with primary insomnia in a 2-week sleep laboratory trial", Sleep, 35, pp.A222~ (2012)
- Krystal AD, "Principles and practice of sleep medicine", pp.842~854 (2017), Elsevier
- Krystal AD, "Effects of antipsychotic medications on sleep in schizophrenia", Int Clin Psychopharmacol, 23, pp.150~160 (2008)
- Todder D, "Night locomotor activity and quality of sleep in quetiapine-treated patients with depression", J Clin Psychopharmacol, 26, pp.638~642 (2006)
- Moreno RA, "A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania", Braz J Med Biol Res, 40, pp.357~366 (2007)
- Kirshner HS, "Controversies in behavioral neurology : the use of atypical antipsychotic drugs to treat neurobehavioral symptoms in dementia", Curr Neurol Neurosci Rep, 8, pp.471~474 (2008)
- Smith HS, "Personalized pharmacotherapy for treatment approaches focused at primary insomnia", Am J Ther, 18, pp.227~240 (2011)